EXPERIENCE WITH INTRAPERITONEAL CHEMOTHERAPY USING ASCITIC FLUID AS A SOLVENT OF CHEMICALS IN THE TREATMENT OF OVARIAN CANCER
Thirty two with the ascitic form of Stages IIIC-IV ovarian cancer underwent 1 to 3 courses of intraperitoneal multidrug therapy using a protein ascitic fluid concentrate (PAFC) as a solvent of drugs (cisplatin, cyclophosphan, doxorubicin) according to the CAP regimen. The induction chemotherapy allo...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
ABV-press,
2014-09-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Thirty two with the ascitic form of Stages IIIC-IV ovarian cancer underwent 1 to 3 courses of intraperitoneal multidrug therapy using a protein ascitic fluid concentrate (PAFC) as a solvent of drugs (cisplatin, cyclophosphan, doxorubicin) according to the CAP regimen. The induction chemotherapy allowed remission to be achieved in 78.1% of cases (against 40% with standard intraperitoneal therapy), the stan- dard volume of surgical treatment was performed in 28 (87.5%) patients (21 (70%) receiving the control regime); with the use of PAFC, the size of minimum residual tumour (less than 1 cm) was achieved in 81.3% versus 63.3% with standard intraperitoneal chemotherapy. This treatment enables the use large-dose chemotherapy regimens that cause no severe systemic toxic reactions. The method is highly-effective, low-toxic and may be recommended for the treatment of patients with the ascitic form of Stages III-IV ovarian cancer. |
|---|---|
| Item Description: | 1994-4098 1999-8627 10.17650/1994-4098-2009-0-1-2-98-102 |